Latest news with #RoyalMarsden
Yahoo
3 days ago
- Health
- Yahoo
Prince and Princess of Wales 'consider leaving Adelaide Cottage'
The Prince and Princess of Wales are reportedly considering moving from Adelaide Cottage. The royal couple have lived in the grounds of Windsor Castle for the last three years, but they are now considering relocating to somewhere bigger, with Fort Belvedere - which is located in Windsor Great Park - being tipped as one possible destination. A source told the Mail on Sunday newspaper: "They feel they have outgrown Adelaide Cottage and need somewhere more substantial. "This is the perfect new home for them. It has a swimming pool and tennis court, and Charlotte loves playing tennis." The Prince and Princess of Wales - who have Prince George, 12, Princess Charlotte, ten, and Prince Louis, seven, together - are currently evaluating their options, but no move is imminent. Earlier this year, the Princess announced that she was in remission from cancer. The 43-year-old royal took to social media in January to reflect on her emotional return to the Royal Marsden Hospital in west London, where she received treatment for cancer, and to confirm that she was in remission from the disease. Catherine - who went public with her cancer diagnosis in March 2024 - wrote on X: "I wanted to take the opportunity to say thank you to The Royal Marsden for looking after me so well during the past year. "My heartfelt thanks goes to all those who have quietly walked alongside William and me as we have navigated everything. "We couldn't have asked for more. The care and advice we have received throughout my time as a patient has been exceptional. "In my new role as Joint Patron of The Royal Marsden, my hope is, that by supporting groundbreaking research and clinical excellence, as well as promoting patient and family wellbeing, we might save many more lives, and transform the experience of all those impacted by cancer. "It is a relief to now be in remission and I remain focussed on recovery. As anyone who has experienced a cancer diagnosis will know, it takes time to adjust to a new normal. I am however looking forward to a fulfilling year ahead. There is much to look forward to. Thank you to everyone for your continued support. C (sic)"
Telegraph
22-07-2025
- Health
- Telegraph
The new stage four cancer treatments and what they mean for patients
A stage-four cancer diagnosis once sounded like the end of the road – after all, there is no stage five. When Joe Biden's prostate cancer was recently labelled 'aggressive' and described as having spread to his bones, many assumed the worst. Yet today, thanks to astonishing advances in cancer science, a stage-four label need not mean imminent death. 'Stage four means the cancer has spread to another part of the body further away from where it started,' explains Dr Ben O'Leary, a clinical oncologist at the Royal Marsden and a researcher at The Institute of Cancer Research (ICR). 'Most stage-four cancers still can't be cured, but our deeper understanding of how cancers evolve and grow means many people are living longer. In some cases, we now see responses, and yes, even cures, that weren't thought possible 10 years ago.' What's driving this optimism? Five types of cancer offer a snapshot of progress. Skip to: Prostate cancer Blood cancers Breast cancer Bladder cancer Lung cancer Prostate cancer By the age of 80, half of men harbour cancer in their prostate, though it proves fatal in only a small minority. Even so, around 12,000 men die of metastatic prostate cancer each year in the UK. Dr Anna Wilkins of the ICR and Royal Marsden says metastatic prostate cancer most often spreads to the bones. 'On scans, you can see up to 50 spots all over the skeleton. But there has been big progress in new drugs.' Total testosterone blockade Standard treatment reduces testosterone, the hormone that fuels tumour growth. Abiraterone, developed at the ICR, goes further by blocking its precursor hormones, extending survival significantly. Liquid radiotherapy This exciting development involves injecting patients with a radioactive liquid. Cancer cells 'drink' more of the liquid than healthy cells and the resulting burst of radiation destroys bone metastases. Liquid radiotherapy drug Radium-223 is already available on the NHS, while the even more potent Lutetium-177 PSMA is available privately and awaiting National Institute of Health and Care Excellence (Nice) appraisal. Multimodal first strikes 'We now combine hormone drugs – and sometimes chemotherapy – immediately after diagnosis,' says Dr Wilkins. Even resistant cancers respond to this approach. Treating the original tumour with radiotherapy, even in metastatic cases, also boosts survival: 'It's as if you're silencing a mothership that coordinates the metastases,' she says. While there is no cure yet, Dr Wilkins says, these approaches are turning stage-four prostate cancer into a condition many men will live with, not die from.
Daily Mail
21-07-2025
- Entertainment
- Daily Mail
EXCLUSIVE Oasis megafan with stage 4 cancer who thought he had missed his chance to see the band perform is surprised by childhood friends with tickets
A man with stage four cancer was stunned after being surprised with Oasis tickets after he was too ill to secure them when they went on sale last year. Lee Brown, 50, from Sheffield, was diagnosed in 2016 with gastrointestinal stromal tumour (GIST), a rare type of cancer that develops in the digestive system. The Oasis megafan had a 26cm tumour growing in his stomach and has had three surgeries in the last nine years in an attempt to cure the disease. However, three months ago, Lee and his family were told by medics that his treatment was no longer working. He is now regularly travelling between South Yorkshire and the Royal Marsden Hospital in London for a clinical trial in the hope it will help his cancer. The mental health community team leader was disappointed last August when he was too ill to secure Oasis tickets for their comeback tour this year and thought he had missed his chance to see his favourite band perform once again. That was until his best friends decided to surprise him with tickets to see Liam and Noel Gallagher perform at Heaton Park, Manchester - their home city - on Saturday, after raising money through a secret Just Giving page. Lee told MailOnline: 'Oasis has been the soundtrack of our friendship and our lives. I last saw them in Chicago in 2001. 'I was pretty ill when the tickets went on sale and thought I had missed my chance. Jane did a secret Just Giving appeal for my ticket last week in social media without my knowledge and the £800 was raised in four hours from her making a post, apparently. I can't thank her and everyone who donated enough.' The father-of-three added: 'The concert was everything I thought it would be and more! Words can't do it justice. Unreal!' Lee posted a video on X showing his childhood friends David Wroe, Paul Deacon and Jane Wroe, pulling up to his house blasting Stand By Me clad in Oasis branded merchandise. 'Have you seen him? Have you really come to show off? You're kidding,' Lee said while playfully shaking his head. They then got out of the car before handing him a letter, while saying: 'We've come to show off, we've not got you a ticket, don't be daft, they're like £4,000 each.' He then read Jane's letter aloud and said: 'To my adopted brother Lee, Stop Crying Your Heart Out because you, me and David are off to Heaton Park to see Oasis. There's no-one we'd rather have next to us 'You're more than a brother, you're more than a mate, you're a hero and this is our way of saying thank you for being you. Take your bucket hat because your dream of Oasis is coming true. 'We're going to Rock 'N' Roll Stars. Yes, we'll be filming your reaction, no we won't be deleting the footage ever. There's another surprise at the back of the car.' In the back of Jane and David's car was Lee's other childhood best friend, David, who got out and surprised him with a big, emotional hug. WHAT IS GIST? GIST stands for GastroIntestinal Stromal Tumour. A GIST can occur when special cells within the wall of the gastrointestinal (GI) tract change so that they grow more than they should. GISTS often have no symptoms but it can vary depending on size and location of the tumour. Symptoms: Fatigue (tiredness and a feeling of weakness) Weight loss Tummy (abdominal) discomfort or pain A painless lump in the abdomen Being sick (vomiting) Blood in the stools (bowel motions) or vomit Anaemia (low level of red blood cells) Source: NHS He said: 'David and Paul have been my best mates since eight years of age and Jane is David's sister, who I have known since she was born and see as my own little sister. I also have the best group of friends. It's a unique and strong bond we've all had throughout our lives.' 'My favourite part was my favourite song Live Forever, which is more and more poignant as time goes on. But it was all honestly immense, I sang every word. I hope [Noel and Liam] know how much this has meant to so many people. 'I think in such a tough time in the UK, the [Noel and Liam] need to realise the happiness and magic they have brought back into people's lives and my story is one of many that show that.' Although he had the best time with his closest friends, Lee said that his 'only tinge of sadness' was that he couldn't go with his family, especially his 16-year-old son Freddie 'who shares my deep passion for everything Sheffield Wednesday and Oasis'. He added: 'Hopefully I will still be around the next time they tour and we can share that moment together.' Since being diagnosed with cancer, Lee has raised over £100,000 for different charities, including £20,000 for GIST Cancer UK to help work towards a cure. 'This has all been done with the help of my amazing friends and family,' he said, including his partner Lisa, 50, and his children Hanaa, 29, Lily, 17, Freddie, 16 and his granddaughter Piper, four, who he 'adores'. Lee, his family and his friends are all hopeful that his clinical trial the Royal Marsden Hospital in London will help his cancer. 'It's an amazing hospital and exciting trial, so I remain positive,' he said.
The Independent
11-07-2025
- Health
- The Independent
Mapped: The best and worst performing NHS trusts in England
England 's best and worst performing hospitals for waiting times, cancer treatment and other key targets have been named on a new online dashboard. Trusts have been ranked by seven measures of performance that also include the amount of time patients spend in emergency departments or waiting for diagnostic tests. While the data used to create the league tables, which were published online by NHS England, have always been available, the new system intends to give the public more information on how local NHS services compare. While NHS commentators welcomed greater transparency, they warned that the 'basic rankings' will not give people the full picture of how their local hospital is performing overall. However, this is the first time it has been presented in this format and in a user-friendly way. The latest data shows that: Clatterbridge Cancer Centre, based in Cheshire and Merseyside, topped the list of trusts with the highest proportion of patients in May whose treatment started within 18 weeks (97.4 per cent), followed by the Christie trust in Manchester (95.0 per cent) and the Royal Marsden in London (94.0 per cent); the Robert Jones & Agnes Hunt Orthopaedic Hospital in Shropshire had the lowest (44.5 per cent), followed by Countess of Chester (47.9 per cent) and Milton Keynes University (49.1 per cent). Countess of Chester had the highest percentage of patients in May that had waited more than a year to start treatment (7.6 per cent), followed by Robert Jones & Agnes Hunt (6.9 per cent) and Mid & South Essex (6.8 per cent), while six trusts were tied on 0.0 per cent: Clatterbridge Cancer Centre, Gateshead in Tyne & Wear, Harrogate & District in North Yorkshire, Maidstone & Tunbridge Wells in Kent, South Tyneside & Sunderland and Tameside & Glossop in Greater Manchester & Derbyshire. Queen Victoria Hospital trust, based in West Sussex, had the highest proportion of patients in June who waited less than four hours from arrival at A&E to admission, transfer or discharge (96.4 per cent), followed by Moorfields Eye Hospital in London (96.0 per cent) and Sheffield Children's (93.7 per cent); East Cheshire had the lowest (46.7%), followed by Shrewsbury & Telford in Shropshire (53.0 per cent) and Nottingham University (56.4 per cent). Warrington & Halton Teaching Hospitals in Cheshire had the highest proportion of patients in June who waited over 12 hours from arrival at A&E to admission, transfer or discharge (24.3 per cent), followed by Blackpool Teaching Hospitals (22.5%) and Wirral University (22.3 per cent); Moorfields Eye Hospital had the lowest (0.0 per cent), followed by Northumbria Healthcare (0.2 per cent) and Alder Hey Children's in Liverpool (0.2 per cent). Not all providers submitted data for this measure and the figures are for type 1 (consultant-led major departments) and type 2 (consultant-led specialised services) A&Es only. Bolton trust in Greater Manchester had the highest percentage of patients in May who, after being urgently referred for suspected cancer, were diagnosed or had cancer ruled out within 28 days (89.5 per cent), followed by Kingston & Richmond in London (85.5 per cent) and Bradford Teaching Hospitals in West Yorkshire (84.5 per cent); Medway in Kent had the lowest (53.8 per cent), followed by Hull University Teaching Hospitals (55.6 per cent) and Mid & South Essex (58.8 per cent). These rankings exclude providers that are cancer specialist treatment centres or single speciality trusts. Calderdale & Huddersfield in West Yorkshire had the highest percentage of patients who had waited no longer than 62 days in May from an urgent suspected cancer referral, or consultant upgrade, to their first definitive treatment for cancer (90.3 per cent), followed by Bolton (87.8 per cent) and East & North Hertfordshire (86.9 per cent); Mid & South Essex had the lowest (42.3 per cent), followed by Hull University Teaching Hospitals (46.3 per cent) and Sheffield Teaching Hospitals (47.1%). These rankings exclude providers that are cancer specialist treatment centres or single speciality trusts. West Suffolk had the highest proportion of patients in May who had waited longer than six weeks for any one of 15 standard diagnostic tests, such as an MRI scan, non-obstetric ultrasound or gastroscopy (56.2 per cent), followed by East & North Hertfordshire (53.2 per cent) and King's College in London (49.2 per cent); the lowest was the Clatterbridge Cancer Centre (0.0 per cent), followed by the Royal Orthopaedic Hospital in Birmingham (0.3 per cent) and Moorfields Eye Hospital (0.5 per cent). Daniel Elkeles, chief executive of NHS Providers, said that 'greater transparency is good' but 'there is a risk of comparing apples and pears, as the data doesn't always capture differences between trusts in the services available, particularly for specialist providers'. 'The data must be accurate, too. Even a small error could make a big difference to a trust's 'ranking'. 'Many trusts face particular challenges, for example, as a result of local demographics, staffing or the quality of their buildings and equipment. 'Basic 'rankings' can't give patients the full picture, and it will be important to make sure that this approach doesn't widen the gulf between trusts at the top of the table and those which – often for reasons beyond their control – need more support.' The rankings on these key measures come after Health Secretary Wes Streeting promised to tackle poor performance in the health service. In November, he announced plans to name and shame failing hospitals in league tables and sack NHS managers if they cannot improve patient care and take control of finances. Trusts can expect to be ranked on a range of indicators such as finances, delivery of services, patient access to care and the competency of leadership. These tables are expected to be available by the end of the summer.
The Independent
10-07-2025
- Health
- The Independent
England's best and worst performing NHS trusts ranked on seven key measures
England 's best and worst performing hospitals for waiting times, cancer treatment and other key targets have been named on a new online dashboard. Trusts have been ranked by seven measures of performance that also include the amount of time patients spend in emergency departments or waiting for diagnostic tests. While the data used to create the league tables, which were published online by NHS England, have always been available, the new system intends to give the public more information on how local NHS services compare. While NHS commentators welcomed greater transparency, they warned that the 'basic rankings' will not give people the full picture of how their local hospital is performing overall. However, this is the first time it has been presented in this format and in a user-friendly way. The latest data shows that: Clatterbridge Cancer Centre, based in Cheshire and Merseyside, topped the list of trusts with the highest proportion of patients in May whose treatment started within 18 weeks (97.4%), followed by the Christie trust in Manchester (95.0%) and the Royal Marsden in London (94.0%); the Robert Jones & Agnes Hunt Orthopaedic Hospital in Shropshire had the lowest (44.5%), followed by Countess of Chester (47.9%) and Milton Keynes University (49.1%). Countess of Chester had the highest percentage of patients in May that had waited more than a year to start treatment (7.6%), followed by Robert Jones & Agnes Hunt (6.9%) and Mid & South Essex (6.8%), while six trusts were tied on 0.0%: Clatterbridge Cancer Centre, Gateshead in Tyne & Wear, Harrogate & District in North Yorkshire, Maidstone & Tunbridge Wells in Kent, South Tyneside & Sunderland and Tameside & Glossop in Greater Manchester & Derbyshire. Queen Victoria Hospital trust, based in West Sussex, had the highest proportion of patients in June who waited less than four hours from arrival at A&E to admission, transfer or discharge (96.4%), followed by Moorfields Eye Hospital in London (96.0%) and Sheffield Children's (93.7%); East Cheshire had the lowest (46.7%), followed by Shrewsbury & Telford in Shropshire (53.0%) and Nottingham University (56.4%). Warrington & Halton Teaching Hospitals in Cheshire had the highest proportion of patients in June who waited over 12 hours from arrival at A&E to admission, transfer or discharge (24.3%), followed by Blackpool Teaching Hospitals (22.5%) and Wirral University (22.3%); Moorfields Eye Hospital had the lowest (0.0%), followed by Northumbria Healthcare (0.2%) and Alder Hey Children's in Liverpool (0.2%). Not all providers submitted data for this measure and the figures are for type 1 (consultant-led major departments) and type 2 (consultant-led specialised services) A&Es only. Bolton trust in Greater Manchester had the highest percentage of patients in May who, after being urgently referred for suspected cancer, were diagnosed or had cancer ruled out within 28 days (89.5%), followed by Kingston & Richmond in London (85.5%) and Bradford Teaching Hospitals in West Yorkshire (84.5%); Medway in Kent had the lowest (53.8%), followed by Hull University Teaching Hospitals (55.6%) and Mid & South Essex (58.8%). These rankings exclude providers that are cancer specialist treatment centres or single speciality trusts. Calderdale & Huddersfield in West Yorkshire had the highest percentage of patients who had waited no longer than 62 days in May from an urgent suspected cancer referral, or consultant upgrade, to their first definitive treatment for cancer (90.3%), followed by Bolton (87.8%) and East & North Hertfordshire (86.9%); Mid & South Essex had the lowest (42.3%), followed by Hull University Teaching Hospitals (46.3%) and Sheffield Teaching Hospitals (47.1%). These rankings exclude providers that are cancer specialist treatment centres or single speciality trusts. West Suffolk had the highest proportion of patients in May who had waited longer than six weeks for any one of 15 standard diagnostic tests, such as an MRI scan, non-obstetric ultrasound or gastroscopy (56.2%), followed by East & North Hertfordshire (53.2%) and King's College in London (49.2%); the lowest was the Clatterbridge Cancer Centre (0.0%), followed by the Royal Orthopaedic Hospital in Birmingham (0.3%) and Moorfields Eye Hospital (0.5%). Daniel Elkeles, chief executive of NHS Providers, said that 'greater transparency is good' but 'there is a risk of comparing apples and pears, as the data doesn't always capture differences between trusts in the services available, particularly for specialist providers'. 'The data must be accurate, too. Even a small error could make a big difference to a trust's 'ranking'. 'Many trusts face particular challenges, for example, as a result of local demographics, staffing or the quality of their buildings and equipment. 'Basic 'rankings' can't give patients the full picture, and it will be important to make sure that this approach doesn't widen the gulf between trusts at the top of the table and those which – often for reasons beyond their control – need more support.' The rankings on these key measures come after Health Secretary Wes Streeting promised to tackle poor performance in the health service. In November, he announced plans to name and shame failing hospitals in league tables and sack NHS managers if they cannot improve patient care and take control of finances. Trusts can expect to be ranked on a range of indicators such as finances, delivery of services, patient access to care and the competency of leadership. These tables are expected to be available by the end of the summer.
